Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine

Maren K. Levin1, Kai Wang2, Roman Yelensky2, Ying Cao3, Corinne Ramos4, Nicholas Hoke4, John Pippen Jr1, Joanne L. Blum1, Barry Brooks1, Gary Palmer2, Norma Palma2, Sohail Balasubramanian2, Jeffrey S. Ross2,5 & Joyce O’Shaughnessy1

1Baylor-Sammons Cancer Center, Texas Oncology, US Oncology, Dallas, Texas
2Foundation Medicine Inc., Cambridge, Massachusetts
3Valley Medical Oncology Consultants, Pleasanton, California
4Theranostics Health Inc., Rockville, Maryland
5Albany Medical College, Albany, New York

Keywords
capcitabine, metastatic breast cancer, exceptional responders, DNA damage response, chromatin remodeling genes

Abstract
We analyzed the genomic and phosphoproteomic profiles of breast cancer tissue obtained from six patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer who had highly durable (≥5 years) and, in some cases, ongoing clinical responses with capecitabine. Formalin-fixed, paraffin-embedded tissue samples from patients’ primary (n = 4) or metastatic (n = 2) breast cancers were utilized for targeted next-generation sequencing and reversed phase protein microarray. Two patients received capecitabine monotherapy. Four patients received capecitabine in combination with paclitaxel; three of these continued single-agent capecitabine after stopping paclitaxel. Capecitabine was discontinued for progressive disease after a mean of 66 months in four patients (range 54–86 months), and two patients remain on therapy, having received capecitabine for >91 months and >122 months, respectively. Three patients’ cancers (50%) had likely functional alterations in DNA repair and chromatin remodeling genes, while three other patients’ cancers had variants of unknown significance in these pathways. Mutations in PIK3CA, amplifications of FGFR1 or ZNF703, or phosphorylation of HER family receptors and their downstream proteins did not preclude exceptional responses to capecitabine. None of the patients’ tumors harbored TP53 or PTEN mutations. Four of the patients had breast cancer tissue available for PTEN immunohistochemistry, and all four patients’ cancers were positive for PTEN. These surprising findings in a group of phenotypically similar patients with ER-positive, endocrine therapy-pretreated, HER2-negative metastases, are supported by preclinical data showing that sensitivity to 5-fluorouracil is enhanced by deficiencies in chromatin remodeling and homologous recombination genes. Our findings suggest that mutations that inactivate homologous recombination and/or chromatin remodeling genes within ER-positive, HER2-negative breast cancers may predict for highly durable responses to capecitabine.

Introduction
There is considerable interest in oncology in prospectively identifying genomic alterations that may predict for response to a given therapy, and in selecting patients for standard or investigational therapies based on predefined genetic alterations. There is also an emerging interest in identifying patients who have had an exceptional response
ER-Positive MBC Patients with Exceptional Responses to Capecitabine

M. K. Levin et al.

Methods

Patients with MBC who had received capecitabine mono-therapy or capecitabine in combination with a taxane followed by single-agent capecitabine over the course of at least 5 years were identified from two practices in Texas Oncology. Institutional Review Board-approved informed consent for tissue collection and molecular analysis was obtained in accordance with Baylor University Medical Center requirements.

Formalin-fixed, paraffin-embedded (FFPE) tissue samples were prepared from primary breast cancers \( n = 4 \) or metastatic disease \( n = 2 \) from patients with \( \geq 5 \) years of response to capecitabine as treatment for metastatic disease. Targeted next-generation sequencing (NGS) was carried out at a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory (Foundation Medicine Inc., Cambridge, MA) on at least 50 ng of extracted DNA using the Illumina HiSeq at an average depth exceeding 500× in order to characterize genomic alterations across 287 cancer-related genes. An evaluation of all classes of genomic alterations was performed, including base substitutions, short insertions/deletions, focal amplifications, homozygous deletions, and gene fusions/rearrangements, as previously described [3]. In order to maximize detection accuracy (sensitivity and specificity) in commonly impure clinical specimens, the test was optimized and validated to detect genomic alterations with high accuracy [4].

Phosphoprotein analysis was also performed on the FFPE samples using a reversed phase protein microarray (RPMA) platform at a CLIA-certified laboratory (Theranos Health, Inc., Rockville, MD). Immunostaining was carried out with 14 antibodies directed against specific phosphorylated, cleaved, or total proteins within the HER family (HER1, p-HER1 [Tyr 1068], HER2, p-HER2 (Tyr 1248), HER3, p-HER3 (Tyr 1289), p-Akt (Ser 473), p-mTOR (Ser 2448), p-S6 ribosomal protein (Ser 235–236), p-4E-BP1 (Ser 65), p-MEK1/2 (Ser 217–221), p-ERK1/2 (Thr 202-Tyr 204), p-Jak2 (Tyr 1007–1008), and p-STAT3 (Tyr 705), in order to characterize the activity of downstream signaling pathways known to be involved in breast cancer pathogenesis. The scoring of each analyte was determined by comparing the normalized fluorescence intensity per unit of protein (NFU) value in the patient sample of interest with that of a representative population. The scores assigned corresponded to the number of standard deviations (SD) from the population mean for each analyte.

Phosphatase and tensin homolog (PTEN) immunohistochemistry (IHC; monoclonal antibody, clone 6H2.1) with 0% or ≤50% positive cells was regarded as negative for PTEN staining, and ≥1% and >50% positive cells was regarded as positive. Androgen receptor (AR) IHC (monoclonal antibody AR318) with <10% positive nuclei was regarded as negative for AR staining.

Results

Clinical phenotype

Six postmenopausal patients with MBC who had had exceptional clinical responses to capecitabine, and for whom adequate FFPE archival tissue for molecular analysis existed, were identified (Table S1). Evaluation of the patients’ primary breast cancers, as well as metastatic samples where available, revealed that they were all estrogen receptor (ER) positive and HER2 negative. Five of the six patients (83.3%) had received prior anthracycline and/or taxane therapy, and all six patients (100%) had been previously treated with endocrine therapy before beginning capecitabine. Four patients (66.7%) had received chemotherapy for metastatic disease prior to initiating capecitabine. Initially, all patients received capecitabine twice daily at the standard dosing schedule of 14 days on, 7 days off (see Table S1 for capecitabine doses). Four patients received capecitabine in combination with paclitaxel for a mean of 17 months (range 4–57 months); three of these patients continued with capecitabine mono-therapy for a mean of 86 months (range 59–118 months) after discontinuing paclitaxel for toxicity, and the fourth patient continued with combined capecitabine plus paclitaxel. Two patients received capecitabine as a single agent (54 months and 91+ months, respectively). Five of the patients had liver metastases, two of whom also had bone metastases, and one patient had liver, bone, and chest...
wall involvement. The sixth patient had bone predominant disease. Capecitabine was discontinued after a mean of 66 months in four patients (range 54–86 months), but two patients remain on capecitabine therapy alone, having received treatment for >91 months and >122 months, respectively.

**Genotype analyses**

Cancers from three patients (50%; patients 2, 3, and 4) had likely functional alterations in DNA-damage-response and chromatin remodeling genes (Table 1), which is higher than the published prevalence in ER-positive breast cancer [6]. Three patients’ cancers (50%; patients 1, 5, and 6) had variants of unknown significance (VUS) in DNA repair and chromatin remodeling genes, namely base substitutions, INDELs (insertions or the deletion of multiple bases), or truncations, of unknown functional significance in breast cancer 2, early onset (BRCA2), Fanconi anemia complementation group (FANCF), SET domain containing 2 (SETD2), poly (ADP-ribose) polymerase 1 (PARP1), nuclear receptor corepressor 1 (NCOR1), core-binding factor subunit b (CBFB), and E1A binding protein 300 (EP300). Mutations in the phosphoinositide-3-kinase, catalytic, alpha polypeptide gene (PIK3CA), or amplifications of fibroblast growth factor receptor 1 (FGFR1) or zinc finger protein 703 (ZNF703) genes, did not preclude the development of a highly durable response to capecitabine (Table 1). None of the patients’ tumors carried tumor suppressor 53 (TP53) mutations or homozygous PTEN deletions on NGS.

**Phosphoproteomic analysis**

Evidence of phosphorylation of HER family receptors and their downstream signaling proteins in the patients’ cancers on RPMA analyses was found to not preclude having a highly durable response to capecitabine (Table 2). Activation of HER1, HER2, and HER3 as well as PI3K and signal transducer and activator of transcription 3 (STAT3) pathways was observed in both the primary and even more so in the MBC samples analyzed (Table 2).

Four of the patients had breast cancer tissue available for PTEN IHC, and all four patients’ cancers were positive for PTEN (data not shown). AR expression was negative in the four patients (patients 1, 2, 3, and 5) who had sufficient tissue available for analysis (data not shown).

**Discussion**

Median progression-free survival times for patients with anthracycline- and taxane-pretreated MBC who received single-agent capecitabine in randomized phase II/III clinical trials ranged from 3.1 to 6.6 months [7–12]. Here, we describe six patients with exceptional responses to capecitabine (duration ranging from 54 to >122 months), three of whom had cancers with genomic alterations that likely led to dysfunctional DNA-damage-response (checkpoint and homologous recombination), and chromatin remodeling genes. We are currently exploring the potential function of the DNA damage response and chromatin remodeling VUS observed in the other three patients’ cancers. These surprising findings of very highly durable benefit from capecitabine in a group of phenotypically similar patients with ER-positive, endocrine therapy-pretreated, HER2-negative MBC, are supported by preclinical data showing that sensitivity to 5-fluorouracil (5-FU) is enhanced by deficiencies in chromatin remodeling and/or homologous recombination genes [13]. 5-FU induces double-strand breaks in DNA, which are repaired by homologous recombination or postreplication repair (PRR) [14]. Deficiency in chromatin modifier function decreases chromatin relaxation, preventing access of homologous recombination and PRR proteins to the DNA, thereby interfering with double-strand DNA damage repair. Genomic alterations that decrease the effectiveness of these two DNA repair pathways simultaneously lead to a greater impact on the cell cycle and G2/M replication arrest with 5-FU than do deficits in only one DNA repair pathway [13]. We hypothesize that the chromatin

---

**Table 1. Genomic alterations identified via NGS.**

| Patient | DNA repair | Chromatin remodeling | PI3K pathway | Other genomic alterations |
|---------|------------|----------------------|--------------|--------------------------|
| 1       | [BRCA2, FANCF] | [SETD2] | PIK3CA mutation | MCL1 amplification |
| 2       | CHEK2, PALB2 | [NCOR1, TET2] | – | RB1 deletion |
| 3       | CHEK2 | [BCORL1] | – | – |
| 4       | ATM | EP300 | FGFR1 amplification | MYC, ZNF703 amplifications |
| 5       | [PARP1] | [NCOR1, CBFB] | PIK3CA mutation | CDH1, GATA3 mutations |
| 6       | [SETD2] [5] | [EP300, SETD2] | – | – |

Results in brackets represent variants of unknown significance (VUS). The VUS are short variants defined as base substitutions, INDELs (insertions or the deletion of multiple bases) or truncations, of unknown functional significance.
remodeling and homologous recombination defects observed in our patients’ cancers prevented repair of 5-FU-induced DNA damage by interfering with two key DNA repair pathways (homologous recombination and PRR), leading to marked replication arrest. It is not known whether a single genomic alteration in either a chromatin remodeling or a homologous recombination gene would enhance clinical sensitivity to capecitabine.

Genomic alterations in the PI3K pathway were identified in three of the patients’ cancers, demonstrating that these presumed activating alterations do not preclude prolonged benefit from capecitabine. HER family pathway activation (p-erbB2, p-EGFR, p-HER3) was common in the primary and MBC samples, with downstream activation of p-mTOR and p-STAT3 seen in several patients’ cancers. Four of the patients’ cancers with sufficient tissue available for analysis were positive for PTEN on IHC. This observation raises the question of whether intact PTEN is a requirement for exceptional response to capecitabine. Interestingly, this observed activation of HER family signaling also did not preclude the development of highly durable responses to capecitabine.

We queried The Cancer Genome Atlas (TCGA) ER-positive/HER2-negative breast invasive carcinoma cases [15] using the cbioPortal [16, 17] and found that the DNA repair and chromatin remodeling gene alterations identified in our patients’ cancers occurred in 1% to 4% and in 0% to 5% of TCGA cases, respectively. We did not find evidence of co-occurrence of the DNA repair and chromatin remodeling genomic alterations as observed in the capecitabine exceptional responders in the TCGA ER-positive, HER2-negative primary breast cancers, suggesting that coexpression of these alterations is uncommon.

We analyzed primary or MBC tissues obtained from nine patients who had ER-positive, HER2-negative MBC and whose disease had responded to capecitabine for less than 2 years. None of these patients’ cancers had alterations in chromatin remodeling genes, and only one of the nine cancers contained a somatic mutation in a DNA-damage-response pathway gene, BRCA2 (data not shown).

The interplay between AR and ER expression in breast cancer is under investigation. Four of the patients’ cancers that we were able to examine had no AR staining on IHC. This finding is in contrast to data from a large cohort of breast cancer patients (n = 5521), which revealed the presence of AR expression in approximately 80% of ER-positive cancers on expert central pathology evaluation [18]. Whether the absence of AR in these ER-positive cancers is an essential component of the molecular profiles that characterize these exceptional responders is unknown.

In summary, molecular analyses of cancer tissue obtained from six ER-positive, HER2-negative MBC patients who had exceptional responses to capecitabine suggest that functional alterations in DNA-damage-response and chromatin remodeling genes may predict for prolonged response to capecitabine within this phenotypic context. This report is unusual in reporting six exceptional responders’ common phenotype and genotype, as most reports have described fewer patients with exceptional response [1, 19]. It would be of interest to corroborate these findings by prospectively identifying ER-positive, HER2-negative MBC patients who have liver and/or bone metastases and whose cancers harbor the described genotype, to evaluate their duration of response to capecitabine.

**Acknowledgments**

Support for third-party writing assistance for this short report was provided by F. Hoffmann-La Roche Ltd. This work was supported by a grant from Baylor Charles A. Sammons Cancer Center, Dallas, TX.
Conflict of Interest

GP, NP are employed by Foundation Medicine. KW, RY, SB, JSR are employed by and own stock in Foundation Medicine. JSR has a leadership position and has received research support from Foundation Medicine. ML, YC, SB, JSR are employed by and own stock in Foundation Medicine. KW, RY, GP, NP are employed by Foundation Medicine. M. K. Levin et al. 2015. Cancer Medicine published by John Wiley & Sons Ltd.

References

1. Iyer, G. A. J. Hanrahan, M. I. Milowsky, H. Al-Ahmadi, S. N. Scott, M. Janakiraman, et al. 2012. Genome sequencing identifies a basis for everolimus sensitivity. Science 338:221.
2. O’Shaughnessy, J. A., M. Kaufmann, F. Siedentopf, P. Dalivoust, M. Debled, N. J. Robert, et al. 2012. Capecitabine monotherapy: review of studies in first-line HER2-negative metastatic breast cancer. Oncologist 17:476–484.
3. Lipson, D., M. Capelletti, R. Yelensky, G. Otto, A. Parker, M. Jarosz, et al. 2012. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat. Med. 18:382–384.
4. Frampton, G. M., A. Fichtenholtz, G. A. Otto, K. Wang, S. R. Downing, J. He, et al. 2013. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat. Biotechnol. 31:1023–1031.
5. Carvalho, S., A. C. Vitor, S. C. Sridhara, F. B. Martins, A. C. Raposo, J. M. P. Desterro, et al. 2014. SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint. eLife 10.7554/eLife.02482.
6. Stephens, P. J., P. S. Tarpey, H. Davies, P. Van Loo, C. Greenman, D. C. Wedge, et al. 2012. The landscape of cancer genes and mutational processes in breast cancer. Nature 486:400–404.
7. Blum, J. L., S. E. Jones, A. U. Buxdar, P. M. LoRusso, I. Kuter, C. Vogel, et al. 1999. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J. Clin. Oncol. 17:485–493.
8. Fumoleau, P., R. Largillier, C. Clippe, V. Diéras, H. Orfeuvre, T. Lesimple, et al. 2004. Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer. Eur. J. Cancer 40:536–552.
9. Miller, K. D., L. I. Chap, F. A. Holmes, M. A. Cobleigh, P. K. Marcom, L. Fehrenbacher, et al. 2005. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 23:792–799.
10. Crown, J. P., V. Diéras, E. Staroslawska, D. A. Yardley, T. Bachelot, N. Davidson, et al. 2013. Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J. Clin. Oncol. 31:2870–2878.
11. Pallis, A. G., I. Boukouvalas, A. Ardavanis, I. Varthalitis, N. Malamos, V. Georgoulas, et al. 2012. A multicenter randomized phase III trial of vinorelbine/gemcitabine doublet versus capecitabine monotherapy in anthracycline- and taxane-pretreated women with metastatic breast cancer. Ann. Oncol. 23:1164–1169.
12. Gilabert, M., F. Bertucci, B. Esterni, A. Madroszyk, C. Tarpin, J. Jacquemier, et al. 2011. Capecitabine after anthracycline and taxane exposure in HER2-negative metastatic breast cancer patients: response, survival and prognostic factors. Anticancer Res. 31:1079–1086.
13. Matuo, R., F. G. Sousa, D. Bonatto, A. A. Mielniczki-Pereira, I. Saffi, D. G. Soares, et al. 2013. ATP-dependent chromatin remodeling and histone acetyltransferases in 5-FU cytotoxicity in Saccharomyces cerevisiae. Genet. Mol. Res. 12:1440–1456.
14. Matuo, R., F. G. Sousa, A. E. Escargueil, D. G. Soares, I. Grivicich, J. Saffi, et al. 2010. DNA repair pathways involved in repair of lesions induced by 5-fluorouracil and its active metabolite FdUMP. Biochem. Pharmacol. 79:147–153.
15. The Cancer Genome Atlas. 2012. Comprehensive molecular portraits of human breast tumours. Nature 490:61–70.
16. Gao, J., B. A. Aksoy, U. Dogrusoz, G. Dresdner, B. Gross, S. O. Sumer, et al. 2013. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal. 6:pl1.
17. Cerami, E., J. Gao, U. Dogrusoz, B. E. Gross, S. O. Sumer, B. A. Aksoy, et al. 2012. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2:401–404.
18. O’Shaughnessy, J., Z. Gatalica, J. Kimbrough, and S. Z. Mills. 2013. Comparison of mutations and protein expression in potentially actionable targets in 5500 triple negative vs. non-triple negative breast cancers. Cancer Res 2013: 73(24 Suppl) abstract PD4-1.
19. Imielinski, M., H. Greulich, B. Kaplan, L. Araujo, J. Amann, L. Horn, et al. 2014. Oncogenic and sorafenib-sensitive ARAF mutations in lung adenocarcinoma. J. Clin. Invest. 124:1582–1586.

Supporting Information

Additional Supporting Information may be found in the online version of this article:

Table S1. Clinical histories of the six patients with exceptional responses to capecitabine.